Showing 4991-5000 of 7583 results for "".
- Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiationshttps://practicaldermatology.com/news/20140530-valeant_and_pershing_square_make_revised_offer_for_allergan_contingent_on_good_faith_negotiations/2459224/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of
- Valeant Sells Fillers to Nestle, Ups Allergan Offerhttps://practicaldermatology.com/news/20140530-valeant_sells_fillers_to_nestle_ups_allergan_offer/2459225/Valeant took two significant steps this week in its pursuit of Allergan. In a deal valued at $1.4 billion in cash, Valeant sold the rights to various aesthetic injectables to Nestle. Nestle is expected to operate Restylane, Perlane, Emervel, Sculptra, and Dysport through Galderma. While the dea
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Allergan Physician Customers Voice Strong Support Following Allergan's Rejection of Unsolicited Proposal to Acquire Companyhttps://practicaldermatology.com/news/20140521-allergan_physician_customers_voice_strong_support_following_allergans_rejection_of_unsolicited_proposal_to_acquire_company/2459232/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that it has received a strong outpouring of support from its physician customers, their nurses and office staff members, as well as from patient advocacy groups and medical associations, following the Company's rejection of Val
- New Data Demonstrate Significant Long-term Improvement in Scarring using Neodyne Biosciences embrace® Advanced Scar Therapyhttps://practicaldermatology.com/news/20140519-new_data_demonstrate_significant_long-term_improvement_in_scarring_using_neodyne_biosciences_embrace_advanced_scar_therapy/2459236/Neodyne Biosciences reported a highly significant improvement in scarring for patients treated with embrace® Advanced Scar Therapy versus control at
- ALPHAEON Appoints Board Of Directorshttps://practicaldermatology.com/news/20140513-alphaeon_appoints_board_of_directors/2459240/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, appointed a team of prominent leaders in healthcare and business to its board of directors. The new board is comprised of experts from the healthcare industry, politics, science, and education. In addition, the
- Aldeyra Therapeutics' Lead Candidate NS2 Shows Novel Approach to Treating Dry Skin, Eye Diseaseshttps://practicaldermatology.com/news/20140512-aldeyra_therapeutics_lead_candidate_ns2_shows_novel_approach_to_treating_dry_skin_eye_diseases/2459242/Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM. The study found that topical applicat
- Bayer Acquires Merck's Consumer Care Business in a $14.2 Billion Cash Transactionhttps://practicaldermatology.com/news/20140508-bayer_acquires_mercks_consumer_care_business_in_a_142_billion_cash_transaction/2459244/Bayer is set to purchase the consumer care unit of Merck and Co., Inc. in a transaction valued at $14.2 billion, acquiring popular products in the cold, allergy, sinus & flu, dermatology (including sun care), foot health and gastrointestinal categories. Bayer's acquisition of Merck's OTC products
- Modernizing Medicine's EMA Achieves ONC HIT 2014 Edition EHR Certificationhttps://practicaldermatology.com/news/20140506-modernizing_medicines_ema_achieves_onc_hit_2014_edition_ehr_certification/2459245/Modernizing Medicine's EMA has achieved ONC HIT 2014 Edition Complete EHR certification, meaning that it will be capable of supporting eligible providers and hospitals with meeting the Stage 1 and Stage 2 Meaningful Use measures of the EHR incentive program. EMA version 4.0 and EMA Mobile version 4.
- TetraLogic Pharmaceuticals Presents SHAPE at Annual Society of Investigative Dermatology Meetinghttps://practicaldermatology.com/news/20140506-tetralogic_pharmaceuticals_presents_shape_at_annual_society_of_investigative_dermatology_meeting/2459246/TetraLogic Pharmaceuticals Corporation presented results from the Phase I randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA -IIA Cutaneous T Cell Lymphoma (CTCL) at the annual Society of Investigative Dermatology Meeting, which was held in Albuquerque, New Mexi